Health-related quality of life and work productivity associated with HiSCR and NRS30 response among patients with moderate to severe hidradenitis suppurativa
Journal of the American Academy of Dermatology, June 2017, Volume 76, Issue 6
A recent study related to patient-reported outcomes (PRO) on adalimumab (Humira), an immunosuppressive medication, found that the medication enhances quality of life and work productivity in patients with moderate-to-severe hidradenitis suppurativa (HS). Analysis Group undertook this study in collaboration with AbbVie (manufacturer of Humira) and Dr. Alexandra Kimball, Professor at Harvard Medical School and President and CEO at Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center. The study, "Health-related quality of life and work productivity associated with HiSCR and NRS30 response among patients with moderate to severe hidradenitis suppurativa," was authored by Dr. Kimball, Analysis Group Managing Principal Min Yang and Vice President Yan Song, and Wendell Valdecantos and Arijit Ganguli of AbbVie. Its findings were presented at this year's American Academy of Dermatology Annual Meeting in March, and an abstract of the study was published in the Journal of the American Academy of Dermatology (JAAD) in June.
The study combined data from two phase 3 clinical trials in which 455 patients were either administered adalimumab therapy or a placebo. The study focused on two indicators: NRS30, a measurement of pain control; and Hidradenitis Suppurativa Clinical Response (HiSCR), a measurement of HS lesion control. The study found that both objective disease control and skin-pain control are associated with improved quality of life and work productivity in patients with HS. In addition, patients who had good disease control and who achieved skin-pain control reported additional benefits in patient-reported outcomes. The Analysis Group team had previously worked with Dr. Kimball and AbbVie to assess the validity, responsiveness, and meaningfulness of HiSCR as the clinical endpoint for HS treatment, using phase 2 data. The findings of that study, which played a pivotal role in obtaining FDA approval, were published in the British Journal of Dermatology, with Dr. Kimball once again the lead author.